Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-09
2011-08-09
Kosar, Andrew D (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253010, C514S255050, C514S256000, C544S236000, C544S295000, C544S326000, C544S360000, C544S409000
Reexamination Certificate
active
07994167
ABSTRACT:
The present invention relates to pentafluorosulphanyl-substituted compounds, methods for their production, medicaments containing such compounds and the use of such compounds for producing medicaments.
REFERENCES:
patent: 3073861 (1963-01-01), Raasch
patent: 5741935 (1998-04-01), Bowden et al.
patent: 7622500 (2009-11-01), Gibson et al.
patent: 1 627 869 (2006-02-01), None
patent: WO 02/08221 (2002-01-01), None
patent: WO 02/16318 (2002-02-01), None
patent: WO 02/16319 (2002-02-01), None
patent: WO 03/070247 (2003-08-01), None
patent: WO 03/080578 (2003-10-01), None
patent: WO 03/095420 (2003-11-01), None
patent: WO 2004/024710 (2004-03-01), None
patent: WO 2004/074290 (2004-09-01), None
patent: WO 2004/089877 (2004-10-01), None
patent: WO 2004/103954 (2004-12-01), None
patent: WO 2004/108133 (2004-12-01), None
patent: WO 2005/003084 (2005-01-01), None
patent: WO 2005/007646 (2005-01-01), None
patent: WO 2005/009977 (2005-02-01), None
patent: WO 2005/009980 (2005-02-01), None
patent: WO 2005/009987 (2005-02-01), None
patent: WO 2005/016890 (2005-02-01), None
patent: WO 2005/051390 (2005-06-01), None
Shin, et al., Bradykinin-12-lipoxygenase-VR1 Signaling Pathway for Inflammatory Hyperalgesia, Proceedings of the National Academy of Sciences of the United States of America, vol. 99, No. 15 (2002).
Acs, et al., Trifluoperazine Modulates [3H]Resiniferatoxin Binding by Human and Rat Vanilloid (Capsaicin) Receptors and Affects 45Ca Uptake by Adult Rat Dorsal Root Ganglion Neurones, The J. of Pharmacology and Experimental Therapeutics, vol. 274, No. 3, 1090-1098 (1995).
Park, H. et al., “N-4-Substituted-benzyl-N′-tert-butylbenzyl thioureas as vanilloid receptor ligands: investigation on the role of methanesulfonamido group in antagonistic activity”, Bioorganic & Medicinal Chemistry Letters, 2004, vol. 14, pp. 787-791, Elsevier.
Ryu, C. H. et al., “Chain-branched 1,3-dibenzylthioureas as vanilloid receptor 1 antagonists”, Bioorganic & Medicinal Chemistry Letters, 2004, vol. 14, pp. 1751-1755, Elsevier.
Park, H. et al., “Biarylcarboxybenzamide derivatives as potent vanilloid receptor (VR1) antagonistic ligands”, Bioorganic & Medicinal Chemistry Letters, 2005, vol. 15, pp. 631-634, Elsevier.
Shao, B. et al., “4-(2-Pyridyl)piperazine-1-benzimidazoles as potent TRPV1 antagonistis”, Bioorganic & Medicinal Chemistry Letters, 2005, vol. 15, pp. 719-723, Elsevier.
Bowden, R. D., “A New Method for the Synthesis of Aromatic Sulfurpentafluorides and Studies of the Stability of the Sulfurpentafluoride Group in Common Synthetic Transformations”, Tetrahedron, 2000, vol. 56, pp. 3399-3408, Pergamon.
International Preliminary Report on Patentability including English translation (Seven (7) pages).
G. Ahern, Activation of TRPV1 by the Satiety Factor Oleoylethanolamide, The Journal of Biological Chemistry, vol. 278, No. 33, Aug. 15, pp. 30429-30434.
L.A. Birder et al., Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1, Nature Neuroscience, vol. 5, No. 9, Sep. 2002, pp. 856-860.
M. Fu et al., TRPV1: A potential target for antiepileptogenesis, Medical Hypotheses 73 (2009), pp. 100-102.
J. Ghilardi et al., Selective Blockade of the Capasicin Receptor TRPV1 Attenuates Bone Cancer Pain, The Jounral of Neuroscience, Mar. 23, 2005, vol. 25, No. 12, pp. 3126-3131.
M. Gunthorpe et al., Characterization of SB-705498, a Potent and Selective Vanilloid Receptor-1 (VR1/TRPV1) Antagonist That Inhibits the Capsaicin-, Acid0, and Heat . . . , J. Pharmacology and Experimental Therapeutics, vol. 321, No. 3, pp. 1183-1192 (2007).
P. Holzer, TRPV1 and the gut: from a tasty receptor for a painful vanilloid to a key player in hyperalgesia,European Journal of Pharmacology 500, 2004, pp. 231-241 (2004).
F. Leung, Capsaicin-sensitive intestinal mucosal afferent mechanism and body fat distribution, Life Sciences 83 (2008), pp. 1-5.
C. Maggi, Therapeutic Potential of Capsaicin-like Molecules: Studies in Animals and Humans, Life Sciences, vol. 51, pp. 1777-1781 (1992).
R. Marsch et a., Reduced Anxiety, Conditioned Fear, and Hippocampal Long-Term Potentiation in Transient Receptor Potential Vanilloid Type 1 Receptor-Deficient Mice, The Journal of Neuroscience, Jan. 24, 2007, vol. 27, No. 4, pp. 832-839.
V. Micale et al., Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: Possible involvement of the endocannabinoid and endovanilloid systems, Neurobiology of Disease 36 (2009), pp. 70-80.
H. Pan et al., Sensing Tissue Ischemia: Another New Function for Capsaicin Receptors?, Circulation Journal of the American Heart Association, Circulation 2004, vol. 110, Issue 13, pp. 1826-1831.
R. Planells-Cases et al., Functional aspects and mechanisms of TRPV1 involvement in neurogenic inflammation that leads to thermal hyperalgesia, Pflugers Arch—Eur J. Physiol (2005) vol. 451, pp. 151-159.
H. Rami et al., The therapeutic potential of TRPV1 (VRI) antagonists: clinical answers await, Drug Discover Today: Therapeutic Strategies, vol. 1, No. 1, 2004, pp. 97-104.
H. Schultz, The spice of life is at the root of cardiac pain, Journal of Physiology (2003), 551.2, p. 400.
T. Sprenger et al., Migraine pathogenesis and state of pharmacological treatment options, BMC Medicine 2009, 7:71.
A. Suri et al., The emerging role of TRPV1 in diabetes and obesity, TRENDS in Pharmacological Sciences, vol. 29, No. 1, pp. 29-36 (2007).
Frank Robert
Schick Hans
Sundermann Bernd
Crowell & Moring LLP
Gruenenthal GmbH
Kosar Andrew D
Leeser Erich A
LandOfFree
Pentafluorosulphanyl-substituted compound and its use for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pentafluorosulphanyl-substituted compound and its use for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pentafluorosulphanyl-substituted compound and its use for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2780912